Healthcare
Venus Medtech (Hangzhou) Inc.(VMTHF)
Live Price
Offline$0.4219
+0.00% today
1Y Change
+67.95%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $690.00M
- Revenue Growth
- -36.5%
- EPS Growth
- +44.2%
- Dividend Yield
- 0.0%
Coverage: 252 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Venus Medtech (Hangzhou) Inc. (VMTHF) is a Healthcare stock with a market cap of $690.00M and listed on OTC. The stock last traded around $0.42 and up 68.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -36.5%, EPS growth of +44.2%, a dividend yield of 0.0%. What stands out right now is revenue -36.5%, EPS +44.2%, free cash flow -1764.0% with operating margin -112.5% and ROIC -14.8%. Valuation is more restrained than many high-expectation growth names at price/sales 2.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VMTHF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-36.5% vs +7.6% peer median
Operating Margin
Below sector median
-112.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Mar 31, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -36.5% and EPS is at +44.2%, with operating margin around -112.5%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 27, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +35.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 31, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Sep 1, 2025 | +12.1% | +0.0% | +106.8% | +106.8% |
2025 Mar 28, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VMTHF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VMTHF Max Drawdown
-48.40%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VMTHF and SPY.
Company Overview
Venus Medtech (Hangzhou) Inc.
Other OTC
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
- Leadership
- Hou-Sen Lim MEng.
- IPO Date
- Apr 30, 2021
- Employees
- 691
- Street Address
- No. 88, Jiangling Road
- Mailing
- Hangzhou, 31005
- Region
- Hangzhou, CN
- Reporting Currency
- USD
- Investor Line
- 86 57 1877 72180
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.3
- Price/Book
- 0.4
Growth
- Revenue
- -36.5%
- EPS
- +44.2%
- Free Cash Flow
- -1764.0%
Profitability
- Gross Margin
- 57.6%
- Operating Margin
- -112.5%
- Net Margin
- -132.3%
- ROE
- -21.1%
- ROIC
- -14.8%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 2.77
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.